Health and Fitness Health and Fitness
Mon, August 8, 2011
Sun, August 7, 2011
Sat, August 6, 2011
Fri, August 5, 2011
Thu, August 4, 2011
Wed, August 3, 2011
Tue, August 2, 2011
Mon, August 1, 2011
Sun, July 31, 2011
Fri, July 29, 2011
Thu, July 28, 2011
Wed, July 27, 2011
[ Wed, Jul 27th 2011 ] - Market Wire
00 AM EDT
Tue, July 26, 2011
Mon, July 25, 2011
Sat, July 23, 2011
Fri, July 22, 2011
Thu, July 21, 2011
Wed, July 20, 2011
[ Wed, Jul 20th 2011 ] - Market Wire
Pfizer To Acquire Icagen
[ Wed, Jul 20th 2011 ] - Market Wire
00 a.m. EDT
Tue, July 19, 2011
Mon, July 18, 2011
[ Mon, Jul 18th 2011 ] - Market Wire
Aetna to Acquire PayFlex
Fri, July 15, 2011
Thu, July 14, 2011
Wed, July 13, 2011
Tue, July 12, 2011
Mon, July 11, 2011
[ Mon, Jul 11th 2011 ] - Market Wire
August 1, 2011

Watson Confirms JALYNa" Patent Challenge


//health-fitness.news-articles.net/content/2011/07/22/watson-confirms-jalyna-patent-challenge.html
Published in Health and Fitness on Friday, July 22nd 2011 at 18:20 GMT by Market Wire   Print publication without navigation


Watson Confirms JALYNa" Patent Challenge -- PARSIPPANY, N.J., July 22, 2011 /PRNewswire/ --

Watson Confirms JALYNa" Patent Challenge

[ ]

- Paragraph IV Litigation Underway -

PARSIPPANY, N.J., July 22, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: [ WPI ]) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market  dutasteride and tamsulosin hydrochloride capsules. Watson's dutasteride and tamsulosin hydrochloride capsules are a generic version of GlaxoSmithKline's JALYN™. JALYN™ capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

(Logo: [ http://photos.prnewswire.com/prnh/20100121/LA41294LOGO ])

GlaxoSmithKline filed suit against Watson on July 21, 2011 in the United States District Court for the District of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 5,565,467. GlaxoSmithKline's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until December 30, 2013, or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  

For the twelve months ending May 31, 2011, JALYN™ capsules had total U.S. sales of over $30 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at [ http://www.watson.com ].

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

JALYN™ is a trademark of GlaxoSmithKline.

CONTACTS:

Investors:
Patty Eisenhaur
(862) 261-8141

Media:
Charlie Mayr
(862) 261-8030

SOURCE Watson Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.watson.com ]


Publication Contributing Sources